遗传决定的血浆肝细胞生长因子水平与缺血性卒中的风险和预后相关
基于21 758名欧洲参与者的全基因组关联研究数据,选取13个与血浆肝细胞生长因子(HGF)相关的单核苷酸多态性作为遗传工具,采用孟德尔随机化分析探讨遗传决定的血浆HGF水平与缺血性卒中风险及预后的关联。结果显示,遗传决定的高HGF水平与缺血性卒中风险增加(每SD增加的比值比1.11,95%CI 1.04-1.19,P=1.10×10-3)及不良预后(每SD增加的比值比2.43,95%CI 1.76-3.52,P=6.35×10-8)相关。
要点
- 遗传决定的高血浆HGF水平与缺血性卒中风险增加相关(每SD增加OR 1.11,95%CI 1.04-1.19)。
- 遗传决定的高血浆HGF水平与缺血性卒中不良预后相关(每SD增加OR 2.43,95%CI 1.76-3.52)。
- 遗传决定的血浆HGF水平与大动脉粥样硬化型卒中高风险相关(每SD增加OR 1.39,95%CI 1.18-1.63),与小血管型及心源性栓塞型卒中无显著关联。
核心结论
- 遗传决定的血浆HGF水平与缺血性卒中的风险和预后呈正相关,提示HGF可能参与缺血性卒中的发生和发展。
研究设计与样本
- 孟德尔随机化分析,基于21 758名欧洲参与者的全基因组关联研究数据选取13个与血浆HGF相关的单核苷酸多态性作为遗传工具。
- 缺血性卒中风险数据来自MEGASTROKE联盟(34 217例缺血性卒中病例和406 111名欧洲血统对照),预后数据来自GISCOME研究(6165例欧洲缺血性卒中患者)。
- 采用逆方差加权孟德尔随机化分析,并进行系列敏感性分析。
主要发现
- 遗传决定的高HGF水平与缺血性卒中风险增加相关(每SD增加的比值比1.11,95%CI 1.04-1.19;P=1.10×10-3)。
- 遗传决定的高HGF水平与缺血性卒中不良预后相关(每SD增加的比值比2.43,95%CI 1.76-3.52;P=6.35×10-8)。
- 遗传决定的血浆HGF水平与大动脉粥样硬化型卒中高风险相关(每SD增加的比值比1.39,95%CI 1.18-1.63;P=5.08×10-5),与小血管型卒中和心源性栓塞型卒中无显著关联。
- 孟德尔随机化-Egger回归显示所有关联均无方向性多效性,不同孟德尔随机化方法的敏感性分析进一步证实了这些发现。
关键数值与推荐
- 缺血性卒中风险:每SD增加HGF的比值比1.11(95%CI 1.04-1.19;P=1.10×10-3)。
- 缺血性卒中预后:每SD增加HGF的比值比2.43(95%CI 1.76-3.52;P=6.35×10-8)。
- 大动脉粥样硬化型卒中风险:每SD增加HGF的比值比1.39(95%CI 1.18-1.63;P=5.08×10-5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies suggest that hepatocyte growth factor (HGF) is associated with the risk and prognosis of ischemic stroke, but the causality of these associations remains unclear. Therefore, we conducted Mendelian randomization (MR) analyses to explore the associations of genetically determined plasma HGF levels with the risk and prognosis of ischemic stroke. METHODS: A total of 13 single-nucleotide polymorphisms associated with plasma HGF were selected as genetic instruments based on the data from a genome-wide association study with 21 758 European participants. Summary data about the risk of ischemic stroke were obtained from the MEGASTROKE (Multiancestry Genome-Wide Association Study of Stroke) Consortium with 34 217 ischemic stroke cases and 406 111 controls of European ancestry, and summary data about the prognosis of ischemic stroke were obtained from the GISCOME study (Genetics of Ischaemic Stroke Functional Outcome) with 6165 European patients with ischemic stroke. We conducted an inverse-variance weighted Mendelian randomization analysis followed by a series of sensitivity analyses to evaluate the associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke. RESULTS: The primary analyses showed that genetically determined high HGF was associated with an increased risk of ischemic stroke (odds ratio per SD increase, 1.11 [95% CI, 1.04-1.19]; P=1.10×10-3) and poor prognosis of ischemic stroke (odds ratio per SD increase, 2.43 [95% CI, 1.76-3.52]; P=6.35×10-8). In the secondary analysis, genetically determined plasma HGF was associated with a high risk of large atherosclerotic stroke (odds ratio per SD increase, 1.39 [95% CI, 1.18-1.63]; P=5.08×10-5) but not small vessel stroke and cardioembolic stroke. Mendelian randomization-Egger regression showed no directional pleiotropy for all associations, and the sensitivity analyses with different Mendelian randomization methods further confirmed these findings. CONCLUSIONS: We found positive associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke, suggesting that HGF might be implicated in the occurrence and development of ischemic stroke.
引用
- Xu Q, Guo D, Shi M, et al. Genetically Determined Plasma Hepatocyte Growth Factor Levels Are Associated With the Risk and Prognosis of Ischemic Stroke. Stroke. 2024. PMID: 38572663. doi:10.1161/STROKEAHA.123.045430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。